rian.ie - Results

A A A

Current Search:	'Cancer' in all fields;

Displaying Results 176 - 200 of 2057 on page 8 of 83

Mark

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. (2015)

Johnstone, Cameron N; Smith, Yvonne E; Cao, Yuan; Burrows, Allan D; Cross, Ryan SN; Lin...

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. (2015)

Johnstone, Cameron N; Smith, Yvonne E; Cao, Yuan; Burrows, Allan D; Cross, Ryan SN; Ling, Xiawei; Redvers, Richard P; Doherty, Judy P; Eckhardt, Bedrich L; Natoli, Anthony L; Restall, Christina M; Lucas, Erin; Pearson, Helen B; Deb, Siddhartha; Britt, Kara L; Rizzitelli, Alexandra; Li, Jason; Harmey, Judith H; Pouliot, Normand; Anderson, Robin L

Abstract:

The original article is available at <a href="http://www.biologists.com">www.biologists.com</a>
The translation of basic research into improved therapies for breast cancer patients requires relevant preclinical models that incorporate spontaneous metastasis. We have completed a functional and molecular characterisation of a new isogenic C57BL/6 mouse model of breast cancer metastasis, comparing and contrasting it with the established BALB/c 4T1 model. Metastatic EO771.LMB tumours were derived from poorly metastatic parental EO771 mammary tumours. Functional differences were evaluated using both in vitro assays and spontaneous metastasis assays in mice. Results were compared to non-metastatic 67NR and metastatic 4T1.2 tumours of the 4T1 model. Protein and transcript levels of markers of human breast cancer molecular subtypes were measured in the four tumour lines, as well as p53 (Tp53) tumour-suppressor gene status and responses t...

http://epubs.rcsi.ie/mctart/74

Mark

Lipid Raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. (2012)

Donatello, Simona; Babina, Irina S; Hazelwood, Lee D; Hill, Arnold DK; Nabi, Ivan R; Ho...

Mark

An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. (2011)

Donatello, Simona; Hudson, Lance; Cottell, David C; Blanco, Alfonso; Aurrekoetxea, Igor...

Mark

Development and validation of a clinical prediction rule to identify suspected breast cancer: a prospective cohort study (2014)

Galvin, Rose; Joyce, Doireann; Downey, Eithne; Boland, Fiona; Fahey, Tom; Hill, Arnold K

Mark

South Central Strategic Health Authority: Cancer inequalities (2007)

Oxford Cancer Intelligence Unit

Mark

Reply: cost-effectiveness of population-based screening for colorectal cancer. (2013)

Sharp, Linda; Walsh, Cathal Dominic; Whyte, Sophie; Tilson, Lesley; O'Ceileachair,...

Mark

Exercise in cancer care in Ireland: a survey of oncology nurses and physiotherapists (2014)

O'Hanlon, É.; Kennedy, N.

Mark

Cancer mortality in Ireland: 1976-1986. (1987)

Seymour, Colin; Herity, Bernadette; Moriarty, Michael J.

Mark

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. (2016)

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véro...

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véronique; Dahan, Laetitia; Glehen, Olivier; Vasseur, Frederique; Lacornerie, Thomas; Piessen, Guillaume; El Hajbi, Farid; Robb, William B; Clisant, Stéphanie; Kramar, Andrew; Mariette, Christophe; Adenis, Antoine

Abstract:

The original article is available at www.biomedcentral.com
BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemo...

http://epubs.rcsi.ie/surgart/32

Mark

Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer. (2016)

Boland, Karen; Flanagan, Lorna; McCawley, Niamh; Pabari, Ritesh; Kay, Elaine; McNamara,...

Mark

Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications (2015)

Barat, Ana; Ruskin, Heather J; Byrne, Annette T; Prehn, Jochen HM

Mark

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. (2016)

O'DRISCOLL, LORRAINE

Mark

Identification of pancreatic cancer invasion-related proteins by proteomic analysis (2009)

Walsh, Naomi; O'Donovan, Norma; Kennedy, Susan; Henry, Michael; Meleady, Paula; Cl...

Mark

A promising set of candidate biomarkers of radioresistant prostate cancer (2016)

MC DERMOTT, NIAMH

Mark

In two minds about screening: an investigation of cervical cancer prevention among Irish women (2016)

Kotzur, Marie-Christin

Mark

Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. (2016)

GRAY, STEVEN; O'BYRNE, KEN; BAIRD, ANNE-MARIE

Mark

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. (2017)

Toomey, Sinead; Eustace, Alex J; Fay, Joanna; Sheehan, Katherine M; Carr, Aoife; Milews...

Toomey, Sinead; Eustace, Alex J; Fay, Joanna; Sheehan, Katherine M; Carr, Aoife; Milewska, Malgorzata; Madden, Stephen F; Teiserskiene, Ausra; Kay, Elaine W; O'Donovan, Norma; Gallagher, William; Grogan, Liam; Breathnach, Oscar; Walshe, Janice; Kelly, Catherine; Moulton, Brian; Kennedy, M John; Gullo, Guiseppe; Hill, Arnold DK; Power, Colm

Abstract:

The original article is available at www.biomedcentral.com
BACKGROUND: The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies. METHODS: Baseline tumour biopsies were available from 74 patients with HER2-positive breast cancer who were enrolled in the phase II TCHL neoadjuvant study (ICORG 10-05) assessing TCH (...

http://epubs.rcsi.ie/molmedart/35